logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover
KPTI
Karyopharm Therapeutics Inc.
7.87
1 x 7.86
1 x 7.98
bid
ask
+
0.00
0.00%
09:31 AM
timesize
Ytd6.86%
1y102.19%
7.77
day range
8.15
3.65
52 week range
10.99
Open7.96Prev Close7.87Low7.77High8.15Mkt Cap178.24M
Vol17.38KAvg Vol487.50KEPS-11.61P/E-0.68Forward P/E-0.87
Beta0.80Short Ratio19.48Inst. Own48.24%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1150-d Avg9.12200-d Avg7.611yr Est4.50

KPTI News

Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
zacks.com
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?

Karyopharm Therapeutics (KPTI) saw its shares surge in the last session with trading volume being hi

12 Health Care Stocks Moving In Monday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session

Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's
benzinga.com
Karyopharm Therapeutics Phase 3 SENTRY Trial Of Selinexor Plus Ruxolitinib In Myelofibrosis Accepted

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov
benzinga.com
Karyopharm Therapeutics To Present Results Of Phase 3 SENTRY Trial In Late-Breaking Oral Presentatio

– Selinexor in Combination with Ruxolitinib Demonstrated a Rapid and Near Doubling of Patients Achie

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
benzinga.com
Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript
benzinga.com
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $137.489M Est

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2026 sales outlook from $130.000 million-$150.000 mi
benzinga.com
Karyopharm Therapeutics Q1 EPS $(1.24) Beats $(1.40) Estimate, Sales $35.066M Beat $31.399M Estimate

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(1.24) per share which beat the

Earnings Scheduled For May 14, 2026
benzinga.com
Earnings Scheduled For May 14, 2026
benzinga.com
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Raises Price Target to $13

HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with
benzinga.com
Karyopharm Therapeutics Files Prospectus For Offering $400M Mixed Shelf

https://www.sec.gov/Archives/edgar/data/1503802/000119312526204130/d69189ds3.htm
benzinga.com
Karyopharm Therapeutics Phase 3 SENTRY Trial In Myelofibrosis Accepted For Late-Breaking Oral Presen

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov
benzinga.com
Piper Sandler Reiterates Overweight on Karyopharm Therapeutics, Lowers Price Target to $8

Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Ove
benzinga.com
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $15

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and l
benzinga.com
HC Wainwright & Co. Maintains Buy on Karyopharm Therapeutics, Lowers Price Target to $8

HC Wainwright & Co. analyst Robert Burns maintains Karyopharm Therapeutics (NASDAQ:KPTI) with

Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark
benzinga.com
Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Karyopharm Therapeutics shares fall after mixed Phase 3 SENTRY data show spleen reduction gains but

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session

This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
benzinga.com
This Strategy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts change outlook on top names, including initiations, upgrades, and downgrades. MSTR has a $1
benzinga.com
Rodman & Renshaw Initiates Coverage On Karyopharm Therapeutics with Buy Rating, Announces Price Targ

Rodman & Renshaw analyst Michael King initiates coverage on Karyopharm Therapeutics (NASDAQ:K
benzinga.com
HC Wainwright & Co. Reiterates Buy on Karyopharm Therapeutics, Maintains $15 Price Target

HC Wainwright & Co. analyst Robert Burns reiterates Karyopharm Therapeutics (NASDAQ:KPTI) wit

12 Health Care Stocks Moving In Thursday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session

Karyopharm Therapeutics Q4 Earnings Assessment
benzinga.com
Karyopharm Therapeutics Q4 Earnings Assessment
benzinga.com
Karyopharm Therapeutics Sees FY2026 Sales $130.000M-$150.000M vs $146.862M Est

Karyopharm Therapeutics (NASDAQ:KPTI) sees FY2026 sales of $130.000 million-$150.000 million vs $146
benzinga.com
Karyopharm Therapeutics Q4 EPS $(5.71) Misses $(1.99) Estimate, Sales $34.079M Miss $35.112M Estimat

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(5.71) per share which missed th

Earnings Scheduled For February 12, 2026
benzinga.com
Earnings Scheduled For February 12, 2026

Uncovering Potential: Karyopharm Therapeutics's Earnings Preview
benzinga.com
Uncovering Potential: Karyopharm Therapeutics's Earnings Preview

This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
benzinga.com
This Incyte Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday
benzinga.com
Cantor Fitzgerald Initiates Coverage On Karyopharm Therapeutics with Overweight Rating

Cantor Fitzgerald analyst Yanni Souroutzidis initiates coverage on Karyopharm Therapeutics (NASDA
benzinga.com
Karyopharm Therapeutics Narrows FY2025 Sales Guidance from $140.000M-$155.000M to $145.000M vs $147.

Karyopharm Therapeutics (NASDAQ:KPTI) narrows FY2025 sales outlook from $140.000 million-$155.000 mi

12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com
RBC Capital Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $19

RBC Capital analyst Brian Abrahams maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperf
benzinga.com
Karyopharm Therapeutics Affirms FY2025 Sales Guidance of $140.000M-$155.000M vs $149.328M Est

Karyopharm Therapeutics (NASDAQ:KPTI) affirms FY2025 sales outlook from $140.000 million-$155.000 mi
benzinga.com
Karyopharm Therapeutics Q3 EPS $(3.82) Misses $(3.13) Estimate, Sales $44.000M Beat $41.212M Estimat

Karyopharm Therapeutics (NASDAQ:KPTI) reported quarterly losses of $(3.82) per share which missed th

Earnings Scheduled For November 3, 2025
benzinga.com
Earnings Scheduled For November 3, 2025
benzinga.com
Karyopharm Therapeutics Earnings Preview

This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
benzinga.com
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
benzinga.com
HC Wainwright & Co. Upgrades Karyopharm Therapeutics to Buy, Announces $15 Price Target

HC Wainwright & Co. analyst Robert Burns upgrades Karyopharm Therapeutics (NASDAQ:KPTI) from

benzinga.com
Piper Sandler Reiterates Overweight on Karyopharm Therapeutics, Lowers Price Target to $12

Piper Sandler analyst Edward Tenthoff reiterates Karyopharm Therapeutics (NASDAQ:KPTI) with a Ove
benzinga.com
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $21

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and l

Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026
benzinga.com
Karyopharm Strengthens Balance Sheet With $100 Million Financing To Extend Cash Runway Into 2026

Karyopharm secures $100 million financing, extends cash runway into 2026, projects $42 million–$44 m
benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga.com
12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com
Karyopharm Completes Enrollment In Phase 3 Trial Testing New Combo Therapy For Myelofibrosis Patient

Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering nov
benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga.com
Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $25

Baird analyst Michael Ulz maintains Karyopharm Therapeutics (NASDAQ:KPTI) with a Outperform and l
benzinga.com
Karyopharm Therapeutics Affirms FY2025 Sales Guidance of $140M-$155M vs $145.358M Est

2025 Financial OutlookBased on its current operating plans, Karyopharm expects the following for ful
benzinga.com
Earnings Scheduled For August 11, 2025
benzinga.com
Earnings Scheduled For May 12, 2025